Cargando…
Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes mellitus, as well as the leading diabetes-associated health care cost. The prevalence and associated impact of cardiovascular disease among those with diabetes engenders the need to identify cardiovas...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292223/ https://www.ncbi.nlm.nih.gov/pubmed/30573964 http://dx.doi.org/10.2147/VHRM.S168472 |